Reports
The Global Sarcoma Drugs Market was valued at USD 1,605.1 Million in 2025 and is anticipated to reach a value of USD 3,245.5 Million by 2033 expanding at a CAGR of 9.2% between 2026 and 2033. Growth is primarily driven by expanding targeted therapies, accelerated orphan drug approvals, and increasing adoption of precision oncology supported by biomarker-guided treatment strategies.
The United States dominates the global sarcoma drugs market, accounting for approximately 41% of global therapeutic adoption, supported by strong oncology research infrastructure, orphan drug incentives, and extensive clinical trial activity. More than 48% of active sarcoma drug development programs are concentrated in the U.S., while Japan has strengthened its position through accelerated rare cancer approvals and specialized sarcoma treatment centers. Ongoing geopolitical efforts to localize pharmaceutical manufacturing across North America and Europe are improving supply resilience for high-value oncology medicines.
Strategic investments in precision medicine, orphan drug development, and regional manufacturing capabilities are becoming essential for strengthening long-term competitive positioning.
Market Size & Growth: Valued at USD 1,605.1 million in 2025 and projected to reach USD 3,245.5 million by 2033 at a CAGR of 9.2%, driven by precision oncology, orphan drug innovation, and expanding targeted treatment portfolios.
Top Growth Drivers: Biomarker-guided therapies contribute nearly 37% of new treatment strategies, orphan drug incentives exceed 32% of pipeline activity, and immunotherapy adoption has increased by approximately 28%.
Short-Term Forecast: By 2028, molecular diagnostic turnaround times are expected to improve by nearly 24%, enabling faster treatment selection and reducing delays in personalized therapy initiation.
Emerging Technologies: AI-assisted drug discovery, next-generation sequencing, liquid biopsy, and companion diagnostics are accelerating oncology research and improving patient stratification across advanced sarcoma therapies.
Regional Leaders: North America leads with an estimated USD 1.30 billion opportunity by 2033, Europe exceeds USD 860 million, while Asia-Pacific approaches USD 720 million through expanding rare cancer infrastructure and clinical research.
Consumer/End-User Trends: More than 46% of eligible patients receive biomarker-based treatment selection, reflecting growing adoption of precision oncology across specialized cancer centers.
Pilot/Case Example: In 2025, expanded molecular tumor board implementation improved personalized treatment recommendations by approximately 22% across participating oncology networks.
Competitive Landscape: The top five companies collectively hold approximately 58% market share, with Eli Lilly, Pfizer, Bayer, Eisai, and Johnson & Johnson competing through targeted oncology portfolios and lifecycle expansion.
Regulatory & ESG Impact: Orphan drug pathways have shortened regulatory review timelines by nearly 25%, while decentralized clinical trials continue improving rare cancer patient enrollment.
Investment & Funding: Global oncology investment surpassed USD 9 billion during recent funding cycles, supported by strategic licensing, biopharmaceutical partnerships, and precision medicine expansion.
Innovation & Future Outlook: Cell therapies, antibody-drug conjugates, and next-generation kinase inhibitors are reshaping treatment strategies as pharmaceutical companies strengthen global rare oncology development programs.
Sarcoma drugs are increasingly focused on precision-targeted therapies, kinase inhibitors, immuno-oncology combinations, and biomarker-guided treatment approaches for rare soft tissue and bone cancers. Approximately 44% of late-stage clinical candidates now incorporate companion diagnostics to improve patient selection. Continued regulatory support for orphan medicines and regional manufacturing diversification are strengthening treatment accessibility while setting the stage for broader strategic developments across the global market.
The sarcoma drugs market has become strategically important as pharmaceutical companies prioritize rare oncology portfolios with high clinical differentiation and regulatory incentives. Precision medicine, expanded genomic profiling, and orphan drug frameworks are reshaping competitive dynamics while encouraging greater investment in specialized oncology pipelines. Companies are simultaneously restructuring supply chains to improve manufacturing resilience for high-value biologics and targeted therapies.
Next-generation targeted therapies demonstrate approximately 31% higher progression-free treatment performance than conventional chemotherapy in selected patient populations while reducing severe treatment-related toxicity. North America continues leading clinical innovation through extensive trial infrastructure, whereas Asia-Pacific is expanding specialized oncology centers and molecular diagnostic capabilities to accelerate patient access. Over 45% of newly initiated sarcoma studies now integrate biomarker-based patient selection, improving development efficiency and treatment precision.
Pharmaceutical manufacturers are expanding licensing partnerships, companion diagnostic collaborations, and regional commercialization agreements to strengthen rare cancer portfolios. A growing number of oncology centers are deploying integrated genomic testing alongside multidisciplinary treatment planning, reducing therapy selection time by nearly 20%. Between 2026 and 2028, competitive advantage will increasingly depend on precision diagnostics, differentiated targeted therapies, manufacturing resilience, and strong clinical partnerships that accelerate regulatory execution and market access.
Precision oncology is transforming the sarcoma drugs market as biomarker-guided therapies increasingly replace conventional treatment pathways. Approximately 39% of newly initiated sarcoma clinical studies now incorporate molecular profiling, while targeted therapies account for nearly 35% of investigational oncology pipelines for rare cancers. In the United States, expanded orphan drug incentives and accelerated regulatory pathways continue encouraging investment in innovative sarcoma therapeutics. This shift improves treatment precision, shortens clinical development timelines, and increases commercial viability for specialized therapies. Pharmaceutical companies are responding through licensing agreements, companion diagnostic partnerships, and acquisitions of oncology-focused biotechnology firms. A notable strategic shift involves integrating genomic testing into treatment workflows, allowing companies to differentiate products through precision medicine rather than broad oncology indications.
The rarity of sarcoma significantly limits patient recruitment, increasing clinical development costs and extending commercialization timelines. Nearly 70% of sarcoma subtypes qualify as ultra-rare diseases, while patient enrollment delays prolong approximately 30% of oncology clinical trials targeting these indications. Japan and several European countries continue facing fragmented patient identification due to dispersed treatment centers and inconsistent referral pathways. These structural constraints reduce economies of scale, increase manufacturing costs for niche therapies, and complicate market expansion strategies. Companies are mitigating these challenges through multinational clinical trial networks, centralized rare disease registries, and strategic licensing partnerships that distribute development risks across multiple organizations. Expanding global patient recruitment infrastructure has become a critical operational priority for sustaining pipeline productivity.
Companion diagnostics are creating new commercial opportunities by enabling highly personalized sarcoma treatment strategies. Approximately 46% of late-stage targeted oncology programs now incorporate biomarker-driven patient selection, improving treatment response rates while reducing unnecessary therapy utilization. China is expanding precision medicine infrastructure through national genomic testing initiatives, increasing access to advanced oncology diagnostics across specialized cancer hospitals. Pharmaceutical companies are investing in integrated drug-diagnostic development programs and collaborating with molecular testing providers to accelerate regulatory approvals. AI-assisted genomic interpretation further enhances diagnostic efficiency by reducing variant analysis time by nearly 22%. Organizations that combine therapeutic innovation with precision diagnostics will strengthen physician adoption, improve reimbursement positioning, and establish durable competitive differentiation.
Developing sarcoma therapies requires extensive clinical validation across numerous histological subtypes, creating significant execution complexity. More than 50 recognized sarcoma variants demand subtype-specific evidence, while nearly 34% of investigational therapies require adaptive clinical trial designs to achieve statistically meaningful outcomes. The United States continues expanding decentralized clinical trials, yet global coordination remains challenging due to varying regulatory frameworks and limited specialist treatment centers. These complexities increase operational costs, delay regulatory submissions, and complicate manufacturing planning for highly targeted therapies. Companies must strengthen global trial collaboration, invest in digital patient recruitment platforms, and expand real-world evidence capabilities to accelerate approvals while maintaining scientific rigor and long-term commercial sustainability.
Precision Biomarker Testing Expands Molecular diagnostics are becoming standard across specialized oncology centers, with approximately 44% of eligible sarcoma patients receiving biomarker-guided treatment selection. Digital pathology integration has reduced diagnostic turnaround times by nearly 21%, improving therapy planning. Pharmaceutical companies are strengthening partnerships with diagnostic developers to align targeted therapies with companion testing while responding to evolving regulatory expectations for precision medicine.
Rare Oncology Licensing Accelerates Strategic licensing and co-development agreements are reshaping competitive positioning as nearly 33% of recent rare oncology transactions involve targeted cancer assets. Large pharmaceutical companies increasingly acquire early-stage biotechnology innovations instead of relying solely on internal discovery. This approach shortens development timelines, expands specialized pipelines, and distributes clinical development risks across collaborative ecosystems.
Cell Therapy Research Advances Cellular immunotherapy and engineered immune cell platforms are entering early sarcoma development programs, with approximately 18% of experimental therapies incorporating advanced cell-based technologies. Manufacturing automation has improved production consistency by nearly 16%, supporting scalable clinical supply. Companies are expanding dedicated manufacturing partnerships to strengthen future commercialization readiness for personalized oncology treatments.
Decentralized Trial Networks Grow Digital patient recruitment, remote monitoring, and electronic outcome reporting are improving clinical trial efficiency for rare cancers. Approximately 27% of global sarcoma studies now incorporate decentralized trial elements, reducing patient travel requirements and accelerating enrollment across multiple countries. Pharmaceutical companies are investing in digital trial infrastructure and specialized hospital collaborations to improve operational resilience while expanding access to geographically dispersed patient populations.
Targeted therapy accounted for approximately 48% of the global sarcoma drugs market in 2025, making it the leading treatment category due to its superior clinical efficacy in biomarker-selected patients, favorable safety profile, and expanding regulatory approvals for rare sarcoma subtypes. Tyrosine kinase inhibitors and kinase-targeted medicines have become standard treatment options for gastrointestinal stromal tumors (GIST) and selected soft tissue sarcomas, strengthening physician confidence and long-term adoption. Chemotherapy remains an essential treatment modality for advanced and metastatic cases, particularly where targeted options are unavailable, while immunotherapy continues gaining traction for combination regimens in selected patient populations.
Immunotherapy represents the fastest-growing segment as ongoing clinical studies expand checkpoint inhibitor combinations and personalized immune-based approaches. Approximately 34% of late-stage sarcoma drug pipelines now evaluate immunotherapy combinations, while targeted agents account for nearly 57% of orphan oncology approvals involving rare solid tumors. Pharmaceutical companies are prioritizing precision medicine collaborations, companion diagnostic development, and lifecycle management strategies to strengthen differentiated product portfolios, shifting investment toward biomarker-guided therapies with higher clinical value and commercial sustainability.
According to the American Society of Clinical Oncology (ASCO) 2025 clinical updates, molecular profiling has become an increasingly recommended component of advanced sarcoma management, supporting broader adoption of targeted therapies across specialized oncology centers.
Soft Tissue Sarcoma (STS) represented approximately 61% of the global sarcoma drugs market in 2025, supported by its broader disease prevalence, diverse histological subtypes, and greater availability of approved targeted therapies. The segment continues attracting substantial clinical research activity as pharmaceutical companies prioritize differentiated therapies addressing complex molecular profiles. Gastrointestinal Stromal Tumor (GIST) remains a mature application with well-established kinase inhibitor treatment pathways, while Bone Sarcoma maintains stable demand driven by multimodal treatment approaches integrating surgery, chemotherapy, and targeted medicines where clinically appropriate.
Bone Sarcoma is emerging as the fastest-growing application as precision oncology research expands treatment options for osteosarcoma and Ewing sarcoma. Approximately 29% of ongoing sarcoma clinical trials now focus on bone malignancies, while biomarker-driven patient selection has improved enrollment efficiency by nearly 21%. Drug developers are expanding multinational clinical programs, strengthening academic partnerships, and integrating genomic diagnostics to accelerate development across underserved sarcoma indications with high unmet clinical need.
The National Comprehensive Cancer Network (NCCN) continued expanding molecular testing recommendations during 2025, reinforcing precision treatment selection for multiple soft tissue and bone sarcoma subtypes.
Specialty cancer centers accounted for approximately 54% of the global sarcoma drugs market in 2025, reflecting their concentration of multidisciplinary oncology expertise, advanced diagnostic infrastructure, and access to complex targeted therapies and clinical trials. These institutions manage high-acuity sarcoma cases requiring molecular diagnostics, specialized pathology, and coordinated treatment planning. Hospitals remain significant purchasers due to broad oncology service coverage and expanding precision medicine capabilities, while research institutes continue supporting early-stage drug evaluation and translational oncology programs.
Hospitals represent the fastest-growing end-user segment as healthcare systems increasingly integrate genomic testing, precision oncology platforms, and decentralized cancer care models. Approximately 46% of tertiary hospitals have expanded molecular oncology capabilities over the past two years, while referral volumes for rare cancers have increased by nearly 19%. Pharmaceutical companies are strengthening collaborations with hospital networks, expanding medical education initiatives, and supporting companion diagnostic deployment to improve treatment accessibility and physician adoption across broader healthcare ecosystems.
A 2025 European Society for Medical Oncology (ESMO) assessment highlighted that multidisciplinary sarcoma referral centers consistently achieved higher utilization of biomarker-guided treatment pathways, reinforcing the growing role of specialized oncology infrastructure in rare cancer management.
North America accounted for the largest market share at 42.6% in 2025 however, Asia-Pacific is expected to register the fastest growth, expanding at a CAGR of 10.4% between 2026 and 2033.
Precision Oncology Infrastructure Strengthens Rare Cancer Leadership
North America accounted for approximately 42.6% of the global sarcoma drugs market, supported by extensive oncology research infrastructure, strong orphan drug development, and widespread adoption of precision medicine. The region maintains the highest concentration of sarcoma clinical trials, molecular diagnostic laboratories, and specialized cancer centers treating rare malignancies. Nearly 58% of newly initiated global sarcoma clinical studies involve North American institutions, accelerating regulatory submissions and commercialization of targeted therapies. Pharmaceutical companies continue expanding collaborations with academic hospitals while investing in companion diagnostics and decentralized clinical trial platforms. Recent investments in genomic testing infrastructure have increased molecular profiling capacity by approximately 24%, improving patient stratification and supporting broader adoption of personalized sarcoma treatment strategies.
United States Market Outlook: The United States dominates the regional market through its leadership in oncology drug innovation, orphan drug incentives, and integrated cancer research networks. Approximately 72% of North American sarcoma drug clinical programs are conducted in the country, supported by specialized comprehensive cancer centers and biotechnology partnerships. Pharmaceutical companies continue expanding precision oncology portfolios, licensing targeted therapies, and strengthening biomarker-driven development programs to accelerate rare cancer treatment availability.
Collaborative Research Networks Accelerate Clinical Innovation
Europe represents approximately 28% of the global sarcoma drugs market, driven by coordinated rare cancer research, advanced healthcare systems, and expanding precision oncology programs. Cross-border clinical collaboration has strengthened patient recruitment for low-incidence cancers while supporting efficient evaluation of targeted therapies. Nearly 35% of European sarcoma studies incorporate multinational research networks, improving access to specialized treatment and molecular diagnostics. Pharmaceutical companies continue expanding collaborations with academic institutions while integrating genomic testing into routine oncology workflows to strengthen personalized treatment selection and regulatory alignment.
Germany Market Outlook: Germany serves as Europe's leading sarcoma drugs market due to its advanced oncology infrastructure, robust pharmaceutical manufacturing, and extensive translational research capabilities. Approximately 29% of European rare oncology clinical research activity is concentrated in Germany. Companies continue investing in precision diagnostics, hospital-based molecular testing, and academic-industry collaborations to accelerate innovative sarcoma therapy development and patient access.
Healthcare Modernization Expands Precision Oncology Access
Asia-Pacific accounts for approximately 21% of the global sarcoma drugs market and is rapidly strengthening its position through expanding oncology infrastructure, precision medicine initiatives, and domestic biopharmaceutical innovation. China, Japan, South Korea, and Australia continue increasing investment in genomic diagnostics, specialized oncology hospitals, and orphan drug research. Approximately 41% of newly established molecular pathology laboratories across the region now support advanced cancer diagnostics, improving treatment selection for rare tumors. Pharmaceutical companies are expanding regional clinical development, licensing partnerships, and localized manufacturing capabilities to improve long-term market accessibility.
China Market Outlook: China has become the region's most strategically significant market through expanding biotechnology investment, accelerated orphan drug approvals, and modernization of oncology care infrastructure. More than 32% of Asia-Pacific oncology clinical trial expansion during recent years has been concentrated in China. Domestic and multinational pharmaceutical companies continue strengthening precision medicine partnerships and increasing localized production of innovative oncology medicines to support broader patient access.
Specialized Cancer Care Gains Momentum
South America represents approximately 4.9% of the global sarcoma drugs market, supported by gradual expansion of specialized oncology services and increasing access to targeted cancer therapies. Governments and healthcare providers are strengthening referral pathways for rare cancers while improving diagnostic capabilities through centralized treatment centers. Approximately 22% of recent oncology infrastructure investments across major markets have supported advanced pathology and molecular diagnostic services. Pharmaceutical companies are expanding medical education initiatives and patient support programs to improve treatment adoption despite reimbursement constraints and uneven healthcare access.
Brazil Market Outlook: Brazil leads the South American market through its large oncology treatment network, growing pharmaceutical industry, and expanding clinical research ecosystem. Approximately 57% of regional oncology referral centers are located in Brazil, supporting greater access to specialized sarcoma care. Companies continue collaborating with tertiary hospitals, expanding clinical trial participation, and improving access to innovative targeted therapies through public-private healthcare partnerships.
Healthcare Investment Strengthens Rare Oncology Capacity
The Middle East & Africa accounts for approximately 3.5% of the global sarcoma drugs market, supported by expanding oncology infrastructure, healthcare modernization programs, and growing investment in specialized cancer treatment facilities. Countries are strengthening rare disease management through centralized oncology centers, digital health integration, and improved diagnostic capabilities. Nearly 18% of recent tertiary healthcare expansion projects across leading regional markets include advanced oncology treatment infrastructure. Pharmaceutical companies continue developing regional partnerships, physician education programs, and market access strategies to improve availability of innovative sarcoma therapies.
Saudi Arabia Market Outlook: Saudi Arabia is emerging as the region's leading sarcoma drugs market through sustained healthcare investment, national biotechnology initiatives, and modernization of specialized oncology services. Approximately 26% of newly commissioned comprehensive cancer care capacity within the Gulf region has been developed in Saudi Arabia. Healthcare institutions are expanding genomic testing, multidisciplinary oncology programs, and international research collaborations to strengthen precision cancer treatment while improving long-term access to innovative rare oncology therapies.
Global oncology leaders including Eli Lilly, Bayer, Pfizer, Eisai, and Johnson & Johnson compete directly in targeted sarcoma therapies, while biotechnology innovators such as Adaptimmune and Deciphera challenge established pharmaceutical companies through precision oncology and cell-based platforms. The top five companies collectively account for approximately 61% of the global market. Competition centers on clinical differentiation, orphan drug exclusivity, biomarker integration, and regulatory execution rather than pricing alone. Precision-targeted therapies improve progression-free outcomes by nearly 30%, while companion diagnostics increase eligible patient identification by approximately 24%. Companies are expanding through licensing agreements, oncology acquisitions, clinical partnerships, and biomarker collaborations to strengthen rare cancer portfolios. The competitive landscape is shifting from conventional chemotherapy toward targeted therapies, engineered cell therapies, and antibody-drug conjugates, increasing pressure on companies lacking precision oncology capabilities. Limited patient populations, lengthy clinical validation, and complex regulatory pathways remain significant entry barriers. Sustainable competitive advantage depends on differentiated clinical evidence, companion diagnostics, rapid regulatory execution, specialized commercialization, and strategic research collaborations.
Eli Lilly and Company
Bayer AG
Pfizer Inc.
Eisai Co., Ltd.
Johnson & Johnson
Novartis AG
Bristol Myers Squibb
Merck & Co., Inc.
Adaptimmune Therapeutics plc
Deciphera Pharmaceuticals, Inc.
Karyopharm Therapeutics Inc.
PharmaMar S.A.
Daiichi Sankyo Company, Limited
GSK plc
Precision oncology technologies currently dominate the sarcoma drugs market through genomic sequencing, companion diagnostics, and biomarker-guided treatment selection. Approximately 47% of advanced sarcoma treatment programs now integrate molecular profiling before therapy selection, improving treatment precision while reducing ineffective drug utilization. AI-assisted genomic interpretation shortens biomarker analysis time by nearly 21%, enabling faster clinical decision-making and improving patient stratification across specialized oncology centers. Pharmaceutical companies gain operational advantages by integrating diagnostics with targeted drug development, accelerating regulatory pathways and improving commercial differentiation.
Emerging technologies include engineered T-cell therapies, antibody-drug conjugates, AI-driven drug discovery, and liquid biopsy platforms that enhance personalized treatment strategies. Compared with conventional chemotherapy, targeted therapies improve progression-free clinical outcomes by approximately 31% while reducing severe treatment-related toxicity by nearly 18%. Biotechnology innovators benefit from these technologies through accelerated orphan drug development, whereas established pharmaceutical companies strengthen competitiveness by acquiring precision oncology platforms and expanding companion diagnostic partnerships.
Between 2026 and 2028, RNA-based therapeutics, adaptive clinical trial platforms, digital pathology, and real-world evidence analytics will reshape rare oncology development. Nearly 38% of late-stage sarcoma pipelines now incorporate precision biomarkers or advanced immunotherapy platforms. Organizations investing early in integrated diagnostics, AI-enabled clinical development, and personalized cell therapies will strengthen regulatory success, optimize commercialization, and secure long-term competitive leadership in specialized oncology markets.
July 2024 Adaptimmune Therapeutics received U.S. FDA accelerated approval for TECELRA (afamitresgene autoleucel), the first engineered cell therapy approved for a solid tumor, targeting advanced synovial sarcoma with MAGE-A4-positive disease, establishing a new treatment benchmark. Source: Adaptimmune
January 2025 GSK received FDA Breakthrough Therapy Designation for GSK5764227, its B7-H3 antibody-drug conjugate for relapsed or refractory osteosarcoma, accelerating clinical development for patients progressing after at least two prior therapies. Source: GSK
April 2025 Accord Healthcare received European Commission approval for Trabectedin Accord, a generic version of trabectedin for advanced soft tissue sarcoma, expanding treatment availability across the European Union and strengthening oncology supply capacity. Source: ema.europa.eu
April 2026 Immutep received U.S. FDA Orphan Drug Designation for eftilagimod alfa in soft tissue sarcoma, supporting Phase II development and providing regulatory incentives that strengthen commercialization prospects for rare oncology therapeutics. Source: sec.gov
The report delivers comprehensive analysis of the sarcoma drugs market across treatment types, including chemotherapy, targeted therapy, immunotherapy, hormonal therapy, and emerging precision oncology approaches. It evaluates therapeutic applications covering soft tissue sarcoma, bone sarcoma, gastrointestinal stromal tumors, Kaposi sarcoma, and other rare sarcoma subtypes, while assessing demand across specialty cancer centers, hospitals, research institutes, and other healthcare providers. Regional analysis spans North America, Europe, Asia-Pacific, South America, and the Middle East & Africa, supported by country-level regulatory, clinical, and commercialization assessments. More than 45% of the evaluation focuses on precision medicine and biomarker-guided treatment adoption.
The report further examines genomic diagnostics, companion diagnostics, engineered cell therapies, antibody-drug conjugates, AI-assisted drug discovery, and molecular pathology platforms influencing future market evolution. It benchmarks leading pharmaceutical and biotechnology companies, evaluates deployment trends, clinical pipeline activity, partnership strategies, and innovation priorities, providing actionable intelligence for investment planning, competitive positioning, product expansion, and strategic decision-making across the global sarcoma drugs market between 2026 and 2033.
| Report Attribute/Metric | Report Details |
|---|---|
|
Market Revenue in 2025 |
USD 1,605.1 Million |
|
Market Revenue in 2033 |
USD 3,245.5 Million |
|
CAGR (2026 - 2033) |
9.2% |
|
Base Year |
2025 |
|
Forecast Period |
2026 - 2033 |
|
Historic Period |
2021 - 2025 |
|
Segments Covered |
By Type
By Application
By End-User
|
|
Key Report Deliverable |
Revenue Forecast, Growth Trends, Market Dynamics, Segmental Overview, Regional and Country-wise Analysis, Competition Landscape |
|
Region Covered |
North America, Europe, Asia-Pacific, South America, Middle East, Africa |
|
Key Players Analyzed |
Eli Lilly and Company, Bayer AG, Pfizer Inc., Eisai Co., Ltd., Johnson & Johnson, Novartis AG, Bristol Myers Squibb, Merck & Co., Inc., Adaptimmune Therapeutics plc, Deciphera Pharmaceuticals, Inc., Karyopharm Therapeutics Inc., PharmaMar S.A., Daiichi Sankyo Company, Limited, GSK plc |
|
Customization & Pricing |
Available on Request (10% Customization is Free) |
